1 Min Read
May 30 (Reuters) - CELYAD SA:
* CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.